| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print October 2, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


¶
From The Saban Research Institute of Childrens Hospital,* Los Angeles, California; the Department of Surgery,
Keck School of Medicine, University of Southern California, Los Angeles, California; the University of Mississippi Medical Center,
Jackson, Mississippi; the J. Vernon Luck, Sr., M.D. Research Center of Orthopaedic Hospital,
Los Angeles, California, and the UCLA-Orthopaedic Hospital Department of Orthopaedic Surgery,¶ David Geffen School of Medicine, University of California, Los Angeles, California
| Abstract |
|---|
|
|
|---|
By establishing and using a three-dimensional in vitro fibrin matrix-cell culture model that recapitulates conditions of in vivo fibroplasia, we discovered that keloid fibroblasts not only produce excessive collagen but are also defective in fibrin degradation because of an overexpression of plasminogen activator inhibitor (PAI-1).7 The increased expression of PAI-1 protein is also present in fibroblasts of keloid lesions.24 Importantly, PAI-1 may cause excessive accumulation of newly synthesized collagen by keloid fibroblasts because reducing PAI-1 activity with PAI-1 neutralizing antibody normalizes collagen accumulation by keloid fibroblasts.24 This link between PAI-1 and collagen accumulation represents a novel mechanism participating in keloid pathogenesis.
PAI-1 is the major physiological inhibitor of the plasminogen activator/plasmin protease system.25 Plasmin not only is the primary effective enzyme in fibrinolysis and clot resolution but also participates in the breakdown of other ECM proteins and activates matrix metalloproteinases and growth factors.26 Although a balanced action between plasminogen activator and PAI-1 maintains the normal function of the protease system, altered plasminogen activator/PAI-1 has been implicated in the development of thrombotic diseases and metabolic disorders that are linked with the development of arteriosclerosis,27 cancers,28 and chronic wounds.29 Increased PAI-1 activity has been a hallmark of fibrosis evident by a direct correlation between genetically determined level of PAI-1 and the extent of collagen accumulation that follows inflammation during injury repair in various organs such as liver,30 lung,31 kidney,32 blood vessels,33 and skin.26 In addition to keloids, PAI-1 overexpression has been found in skin fibroblasts of Werners fibrosis and scleroderma.34
PAI-1 is secreted as an active serine protease inhibitor and has a short half-life. Its activity, however, is stabilized by vitronectin (Vn) present both in plasma and ECM.35,36 Recently, PAI-1 has been implicated in modulating urokinase plasminogen activator (uPA) and uPA receptor (uPAR)-mediated cell adhesion and migration independent of its inhibitor function.37 These additional functions of PAI-1 are based on the evidence that both PAI-1 and uPAR bind to Vn through its somatomedin domain adjacent to the RGD site where integrins bind Vn.38,39 Thus PAI-1 has the capacity to influence ECM metabolism and integrin/ligand binding (both Vn-integrin and uPA/uPAR-Vn-integrin) that modulate cell phenotype and affect cell differentiation and/or ECM production.37,39-41 Because ECM synthesis, degradation, and remodeling are essential features of injury repair, we hypothesize that increased PAI-1 is a precursor to elevated collagen accumulation in keloid fibroblasts and that it functions through inhibiting the uPA/plasmin protease cascade and/or modulating Vn-dependent cell adhesion. We have addressed the precursor role and mechanism of PAI-1 by demonstrating i) increased collagen accumulation in normal fibroblasts through viral overexpression of wild-type hPAI-1 (Wt PAI-1) in monolayer culture and fibrin gels, ii) suppression of collagen accumulation by treatment with PAI-1-directed small interfering RNA (siRNA) and short hairpin RNA-containing microRNA sequences (shRNAmir) in PAI-1-overexpressing normal cells, iii) suppression of collagen accumulation in keloid fibroblasts with PAI-1 siRNA, and iv) differences in protease inhibitor (PAI-1INH–) and Vn-binding (PAI-1VN–) mutants of PAI-1 in their capacity to drive increased accumulation of newly synthesized collagen.
| Materials and Methods |
|---|
|
|
|---|
Collagenase type 1 (filtered; 190 U/mg, 13,659 U/vial) was purchased from Worthington Biochemical Corporation (Lakewood, NJ). Dulbeccos PBS (without calcium and magnesium) and Dulbeccos modified Eagles medium (DMEM; 1x with 4.5 g/L glucose, L-glutamine, and sodium pyruvate) were purchased from Mediatech Inc. (Herndon, VA). Fetal bovine serum (FBS) was from Atlas Biologicals (Fort Collins, CO). HEPES-buffered DMEM (HDMEM) was prepared by adding HEPES free-acid (Sigma-Aldrich Co., St. Louis, MO) to DMEM powder (Sigma-Aldrich Co., St. Louis, MO) per the manufactures instructions. Primocin was from InvivoGen (San Diego, CA). ITS+ is a premixed universal culture supplement (BD Biosciences, San Jose, CA), containing 12.5 mg of human recombinant insulin, 12.5 mg of human transferrin, 12.5 µg of selenous acid, 2.5 g of bovine serum albumin, and 10.7 mg of linoleic acid in 20 ml of water. Nylon cell strainers (100 µm) were purchased from BD Biosciences Discovery Labware (Bedford, MA). PicoGreen DNA assay was purchased from Molecular Probes (Eugene, OR). Proteinase K (recombinant PCR grade) was from Roche Diagnostics (Indianapolis, IN). Sources of antibodies were as follows: mouse monoclonal to
-tubulin 1 mg/ml (Abcam, Cambridge, MA); mouse monoclonal to human PAI-1 (catalog no. 612025; BD Biosciences); mouse monoclonal to Lamin A/C (catalog no. 612163; BD Biosciences); anti-mouse IgG, horseradish peroxidase-conjugated antibody (goat antiserum; 1 mg/ml; catalog no.; Sigma-Aldrich Co.); affinity-purified rabbit antibody to collagen type 1 (catalog no. 600-401-103-0.5; Rockland, Gilbertsville, PA); anti-rabbit IgG, horseradish peroxidase-conjugated antibody (Cell Signaling Technology, Danvers, MA). Precision Plus Protein Dual Color molecular weight standards (catalog no. 161-0374) were obtained from Bio-Rad (Hercules, CA).
Human PAI-1 siRNAs, siCONTROL nontargeting siRNA 1, siGLO Green Transfection Indicator, and transfection reagents were purchased from Dharmacon Inc. (Chicago, IL). The sequences of the three siRNAs for human PAI-1 (SERPINE1) gene are J-019376-05 (siRNA5) sense sequence, 5'-CGACAUGUUCAGACAGUUUUU-3', and antisense sequence, 5'-P.AAACUGUCUGAACAUGUCGUU-3'; J-019376-06 (siRNA6) sense sequence, 5'-GCUAUGGGAUUCAAGAUUGUU-3', and antisense sequence, 5'-P.CAAUCUUGAAUCCCAUAGCUU-3'; and J-019476-07 (siRNA7) sense sequence, 5'-CUAGAGAACCUGGGAAUGAUU-3', and antisense sequence, 5'-P.UCAUUCCCAGGUUCUCUAGUU-3'. PAI-1 protease inhibitory activity was determined using Spectrolyse (pL) PAI, which was purchased from American Diagnostica (Stamford, CT). Lentiviral shRNAmir hairpin sequence for PAI-1 645 (V2LHS 111645) is 5'-TGCTGTTGACAGTGAGCGAGGACACCCTCAGCATGTTCATTAGTGAAGCCACAGATGTAATGAACATGCTGAGGGTGTCCCTGCCTACTGCCTCGGA-3' (Open BioSystems, Huntsville, AL).
Fibroblast Isolation
The protocol for obtaining clinical discards of human normal skin, scar, and keloid specimens was approved by the Institutional Review Board of both the Childrens Hospital Los Angeles (T.-L.T.) and University Mississippi Medical Center (A.W.). Samples were kept on ice during shipping and handling. Samples were rinsed with ice-cold Dulbeccos PBS (without calcium and magnesium) to remove blood clots and trimmed by sharp dissection to remove adipose tissue and 2 to 5 mm of tissue from the epidermal surface. Fibroblasts from each keloid specimen were isolated from this core without distinction between central and peripheral progressive regions using collagenase digestion (Worthington Collagenase Type 1-Filtered 190 U/mg and 13,659 U/vial/30 ml HDMEM). Samples were weighed for estimation of the amount of collagenase/HDMEM to be used (2000 U collagenase/g tissue). Samples were subsequently cut and minced into fine pieces with surgical blades and collected in a 50-ml conical tube filled with 20 ml of ice-cold Dulbeccos PBS (without calcium and magnesium). The tube was set on ice undisturbed for 10 minutes to collect tissue fragments, which were subsequently resuspended in an appropriate volume of collagenase/HDMEM solution and incubated at 37°C in a 5% CO2 environment for 2 hours with gentle mixing (collagenase pretreatment step). Tissue fragments were then transferred into fresh collagenase solution (320 U/ml in 10% FBS/HDMEM) and incubated as above for 18 hours. The digested dermal tissues were filtered through a 100-µm cell strainer to separate the released cells from undigested tissue. Cells were collected by centrifugation, resuspended in 10% FBS/DMEM, and cultured in monolayer at 37°C. These freshly isolated and early passage cells (
2 passages) were used in subsequent experiments. For these experiments, cell passage is defined as lifting and transferring confluent cells from one plate into three new culture plates of the equal size every 7 days.
Recombinant Adenovirus and Cell Transduction
The Ad5-based E1-deleted recombinant vector expressing human PAI-1, AdCMVPAI-1 (Wt PAI-1), mutant PAI-1 protein defective in Vn binding (pACCMVPAI-1VN– or PAI-1VN–), mutant PAI-1 protein defective in plasminogen activator inhibition (pACCMVPAI-1INH– or PAI-1INH–), and the empty vector AdRR5 have been described before42 and were kindly provided by Dr. Robert Gerard (University of Texas Southwestern Medical Center, Dallas, TX). pACCMVPAI-1INH– contains the double mutation R346M and M347S, which renders PAI-1 defective in serpin function. The PAI-1 inhibitory activity was confirmed by inhibition of a known quantity of uPA using an indirect chromogenic substrate assay that measures plasminogen activation42 and by the Spectrolyse (pL) PAI assay (American Diagnostica). pACCMVPAI-1VN– encoding PAI-1 with the Q123K mutation is deficient in Vn binding, which was confirmed by Vn-binding assay using human Vn-coated microtiter plates and the monoclonal antibody to human PAI-1 MA-12A4-horseradish peroxidase.42 On receiving the viral stocks, adenoviruses were repurified by plaque purification and two rounds of dilution to 0.5 plaque-forming unit/well and propagated in 293 cells. Viral stocks were stored as lysates in aliquots at –80°C in 10 mmol/L Tris, pH 8.0, 2 mmol/L MgCl2, and 5% sucrose.43 Titers were determined in 293 cells using the Clontech Adeno-X Rapid Titer procedure (BD Biosciences) and corrected to plaque-forming units per milliliter.
Cells were plated in 10% FBS/DMEM in 48-well plates at confluent density (6 x 104 cells/well) by layering beneath 5% FBS/DMEM. Cells were dispensed slowly with an electronic multichannel pipette after placing the tips at the bottom of the wells beneath 5% FBS; this eliminated the uneven plating density within the wells that was caused by the meniscus when cells were plated without the overlay of 5% FBS. Cells were allowed to attach for 24 hours, washed with DMEM, and cultured or infected with viral vectors at the indicated concentrations for 24 hours in 0.125 ml of 0.3% ITS+/DMEM. Subsequently, cells were fed with the testing medium (0.1% ITS+, 1% FBS, 3% FBS, or 10% FBS) for additional time periods as indicated in the legend of each figure with a change of medium every other day.
Preparation of Fibrin Gels
All fibrinogen used was >95% clottable as determined with a previously described procedure.24 Human skin fibroblasts suspended in DMEM were added to a fibrinogen solution at 24°C. Final concentrations of fibrinogen and fibroblasts were 2.5 mg/ml and 0.5 x 106 cells/ml, respectively. Aliquots (80 µl) of the fibroblast/fibrinogen mixtures were placed in wells of 48-well tissue culture plates (Costar, Cambridge, MA) with 1 U of thrombin per sample. Each aliquot occupied an area outlined by an 8-mm-diameter circular score within the well. The preparations were incubated at 37°C for 1 hour in a humidified incubator containing 5% CO2 to ensure polymerization of fibrin. At the end of the incubation period, 0.5 ml of 10% FBS was added to each well to cover the gel and allowed 24 hours for incubation before being infected with adenoviral vectors at the indicated concentrations for 24 hours in 0.125 ml of 0.3% ITS+. Subsequently, cells were fed with the 3% FBS for an additional 6 days with a change of medium every other day.
Collagen Analysis
Accumulation of newly synthesized collagen was determined by monitoring [3H]proline incorporation into pepsin-resistant collagen chains separated by SDS-PAGE. Cells were treated with labeling medium [testing medium plus 62.5 µg/ml β-aminoproprionitrile, 25 µg/ml ascorbate, and 40 µCi/ml [5-3H]proline (Amersham Biosciences, Piscataway, NJ)] over a 24-hour period before the termination of the experiment. Cultures (medium and cell layer, together) were frozen (terminated), thawed, adjusted to 0.5 N acetic acid and 0.5 mg/ml pepsin, and rocked overnight at 4°C. After two cycles of lyophilization in the culture plate, samples were dissolved in 0.25 ml of SDS-PAGE sample buffer without reducing agent at 55°C for 30 minutes before SDS-PAGE, fluorography,43
and digital image analysis of
1(I) collagen bands (identified by prior comparison with authentic collagen standards). Triplicate samples were analyzed separately for statistical analysis or pooled to provide an averaged sample for visualization/analysis. Pooled samples routinely produced values equivalent to the mean of individually analyzed samples, but without data for the SD. DNA content was used to normalize data obtained from cultures of different duration conducted in the presence of different serum concentrations. Pepsin digestion of noncollagenous proteins and acid depurination of DNA occur in the first step of collagen analysis, respectively preventing the use of cellular proteins as loading controls or accurate DNA analysis in aliquots of these samples for data normalization. Consequently, the cell layers of parallel cultures were digested with Proteinase K and analyzed for DNA using Pico Green (Molecular Probes).
Western Blotting
Medium and cell layer samples from cell cultures were separated at the end of each experiment for PAI-1 Western analysis. Cell layers were rinsed once with Dulbeccos PBS (without calcium and magnesium) and then treated in the well with 1x hot SDS-PAGE sample buffer containing 5% β-mercaptoenthanol. Medium samples were also treated with hot SDS-PAGE sample buffer (4x and final concentration, 1x). Proteins were boiled before SDS-PAGE and transferred to nitrocellulose in buffer containing 25 mmol/L Tris base, 0.2 mol/L glycine, 20% methanol (pH 8.5), and 0.02% SDS. Membrane blots were subsequently blocked for 2 hours at 23°C with 5% nonfat dry milk in 50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, and 0.1% Tween 20 (Tris-buffered saline-Tween 20) and incubated with primary antibodies (i.e., 1:1000 dilution of mouse monoclonal to human PAI-1) overnight at 4°C in 5% bovine serum albumin in Tris-buffered saline-Tween 20. After brief washing in Tris-buffered saline-Tween 20, blots were incubated at 23°C for 40 minutes with horseradish peroxidase-coupled second antibody (i.e., 1:3000 dilution of anti-mouse IgG, horseradish peroxidase-conjugated antibody) in 5% nonfat dry milk in Tris-buffered saline-Tween 20. The protein bands in washed blots were visualized on film with chemiluminescence using SuperSignal West Dura substrate (Pierce Biotechnology, Rockford, IL). Membrane blots were reprobed with mouse monoclonal antibody to Lamin A/C (1:1000 dilution) or
-tubulin (1:2000) as interchangeable loading controls. Molecular weight standards were run with each SDS-PAGE gel. Detected antigens exhibited molecular weights of 47 kDa (PAI-1), 74/65 kDa (Lamin A/C), and 52 kDa (
-tubulin). For collagen Western blots, samples were processed as described for collagen analysis (above) until completion of electrophoresis and then processed for Western blotting with an affinity-purified anti-collagen type I antibody (1:1000 dilution). Triplicate samples were analyzed separately or as a physical pool (see collagen analysis, above) by digital image analysis of the protein bands.
Digital Image Analysis
Data recorded on preflashed film, ie, collagen fluorographs and chemiluminescent Western blots, were analyzed by digital image analysis (Kodak 1D Image Analysis Software; Eastman Kodak, Rochester, NY) using multiple exposures of increasing duration such that integrated intensities for bands of interest were in the linear response range of the film. Band intensities from different exposures were indexed using a band at the low end of the linear range in short exposures and the same band at the high end of the linear range in longer exposures. Control and experimental samples were routinely run on the same gel/blot to ensure accurate comparison, and samples common to each pair of gels were included to enable comparison between gels in the same experiment and between gels of all cell strains.
PAI-1 Activity Assay
A two-stage, indirect enzymatic assay, Spectrolyse (pL) PAI (American Diagnostica), was used for the quantitative determination of PAI-1 activity. The PAI-1 activity (IU) is defined as the amount of PAI that inhibits 1 IU of a human single-chain tissue type plasminogen activator as calibrated against the International Standard for tissue type plasminogen activator (National Institute for Biological Standards and Control, Holly Hill, London, UK).
PAI-1 Knockdown by PAI-1 siRNA
Cells were plated using the underlayering technique described above and transfected the next day with siRNA (final concentration 100 nmol/L) in 0.15 ml of 10% FBS using DharmaFECT 1 transfection reagent (Dharmacon Inc.) for 24 hours. After transfection, cells were washed with DMEM and cultured or infected with adenoviral vectors for 24 hours in 0.25 ml of 0.1% ITS+/DMEM. Subsequently, cells were fed with the testing media (1% FBS, 3% FBS, or 10% FBS) for additional time periods indicated in the legend of each figure with a change of medium every other day before termination.
PAI-1 Lentiviral shRNAmir
A lentiviral stock was created by cotransfecting optimized packaging plasmid mix and transfer vector into the TLA-HEK293T cell line (Open Biosystems), to produce replication-incompetent lentivirus. HEK-293T cells were plated at a density of 5.5 x 106 cells per 100-mm plate and transfected with PAI-1-targeted pGIPZ shRNAmir transfer vector (PAI-1 645) or a nonsilencing vector according to the manufacturers protocol (Open Biosystems). Virus was concentrated by PEG precipitation (System Biosciences, Mountain View, CA). For transduction, normal fibroblasts (strain N144) were plated at a density of 8 x 105 cells per 35-mm dish, infected with lentivirus in 2% FBS/DMEM for 24 hours, and expanded by culture in 10%FBS/DMEM. Transduced fibroblasts were selected with puromycin over a 10-day period, resulting in 95 to 100% green fluorescent protein (GFP)-positive cells. These cells were then infected with Wt PAI-1 adenoviral vector [100 multiplicity of infection (moi)] and monitored for PAI-1 and collagen accumulation as described above.
Data Analysis and Statistics
All pairwise mean ± SD comparisons were performed using Students t-test function (two-tailed distribution) with either equal or unequal variance determined by F-test. Differences were considered statistically significant at P
0.05. Statistical analysis for the difference between pooled normal fibroblast strain data and pooled keloid strain data were based on the general linear model of analysis of variance in Minitab. Differences were considered statistically significant at P
0.05.
| Results |
|---|
|
|
|---|
Cell monolayers were used in the current study to bypass the influence of fibrin matrix44
and test directly the link between PAI-1 expression and collagen accumulation. In addition, cell monolayers can be readily varied in size, permit rapid verification of experimental manipulations and retention of cells, and avoid the loss of cells from fibrin gels cultured under serum-free conditions.45
Seven strains each of freshly isolated primary, first, or second passage fibroblasts from normal skin or keloids (Table 1)
were cultured for 2 or 6 days in DMEM containing 0.1% ITS+, 3% FBS, or 10% FBS. The serum-free condition, ie, 0.1% ITS+, was used to reveal the inherent differences in PAI-1 expression and accumulation of newly synthesized collagen between normal and keloid fibroblasts; 3 and 10% FBS were used to determine the effects of serum-derived growth factors. Short-term 2-day cultures were used to investigate the levels of PAI-1 and collagen while fibroblasts established a new matrix environment, and 6-day cultures were used to examine function within this maturing matrix.
|
|
|
The combination of both PAI-1 and collagen accumulation as phenotypic markers allows clear distinction between individual strains of normal and keloid fibroblasts (Figure 2C
; Supplemental Figure S3, see http://ajp.amjpathol.org). In Figure 2C
, keloid fibroblast strains exhibited increases in both markers during the transition from culture in basal, serum-free, ITS+ supplemented medium (open symbols at arrow origin) to culture in 3% FBS (open symbols at the arrowhead), leading to angled arrows. Under both conditions, keloid strains exceeded normal fibroblasts strains cultured in 3% FBS (Figure 2C
, filled symbols). Only keloid strains K-A and K-C3 in 0.1% ITS+ did not exceed the highest normal strains in 3% FBS. Another exception was K-J, which only increased in PAI-1 expression in response to 3% FBS. When evaluated for response to the transition from 3 to 10% FBS, keloid strains in the less stimulatory condition, 3% FBS, again exceeded production of both PAI-1 and collagen accumulation in normal strains in 10% FBS (Supplemental Figure S3). In contrast to the results in Figure 2C
, however, arrows linking keloid strains in 3 and 10% were vertical, indicating only an increase in PAI-1 expression and apparent saturation of the mechanism regulating collagen accumulation by serum. Informative exceptions were the keloid strain K-F and normal strain N-(K-F), which was isolated from the "normal" skin adjacent to K-F. N-(K-F) produced levels of both markers intermediate between other normal and keloid strains and exhibited a similar transition from 3 to 10% FBS when compared with its corresponding keloid strain, K-F. This suggests that such adjacent skin may have begun a transition toward a keloid phenotype, even though apparently normal by visual inspection. Collectively, the results demonstrate that freshly isolated, early passage keloid fibroblasts from a wide range of donors and different sites persistently express higher levels of PAI-1 and collagen than normal fibroblasts, regardless of the presence or concentration of serum during culture and the status of matrix deposition/maturation (day 2 versus 6). The question of whether PAI-1 plays a role in increased collagen accumulation was addressed directly by the following gain- and loss-of-function experiments.
Overexpression of Wild-Type PAI-1 Protein in Normal Fibroblasts Results in Increased Accumulation of Newly Synthesized Collagen
Elevated PAI-1 and collagen in keloid fibroblasts may occur together because both are downstream targets of the pro-fibrotic growth factor TGF-β1 that is present in the serum or because PAI-1 directly stimulates accumulation of newly synthesized collagen. To test the latter hypothesis, we transduced normal fibroblasts with an adenoviral vector expressing the wild-type hPAI-1 gene (Wt PAI-1; gift of Dr. Robert Gerard)42
to increase PAI-1 protein expression in these cells. This approach provided 85% transduction efficiency, and rapid manipulation of PAI-1 expression without consumption of cellular life span and the risk of stable viral integration. In addition, we were able to vary expression by increasing the moi so that PAI-1 expression approached or surpassed that of keloid fibroblasts. Normal fibroblasts infected with adenoviral Wt PAI-1 expressed PAI-1 protein in a dose-dependent manner (5 to 100 moi) in serum-free, 0.1% ITS+-supplemented medium and produced PAI-1 levels at 100 moi that surpassed that of fibroblasts cultured in 10% FBS without virus (Supplemental Figure S4A, see http://ajp.amjpathol.org). Fibroblasts infected with virus at 100 moi and subsequently cultured in 0.1% ITS+, 1% FBS, 3% FBS, or 10% FBS for 48 hours exhibited a serum dose-response superimposed on a 10-fold virus-dependent increase in PAI-1 expression (Supplemental Figure S4, B and C). When this 10-fold increase in PAI-1 is applied to any of the normal strain data in Figure 2B
, the PAI-1 levels approach or exceed those of the keloid strains. A direct comparison within an independent experiment conducted with infection at 100 moi and culture in 3% FBS for a longer 6-day period produced greater than twofold higher PAI-1 levels in virally transduced normal cells than in a keloid strain (Supplemental Figure S4D). Thus, the combined effects of serum, its effects on the CMV viral promoter for PAI-1, and the viral dose were capable of producing PAI-1 levels above that exhibited by keloid fibroblasts.
The effects of PAI-1 overexpression on accumulation of newly synthesized collagen were tested over a broad culture period of 2, 6, and 13 days to mimic the time frame of early wound repair and remodeling and in 1% FBS to minimize effects of serum stimulation, if these exist. Normal fibroblasts were infected with 30, 100, and 300 moi of adenoviral Wt PAI-1 (Ad-Wt PAI-1) or empty vector to vary the PAI-1 dose delivered to the cultured normal fibroblasts (strain N144). A viral dose-response was observed from days 2 to 13, with PAI expression reaching a maximum at day 6 and declining only slightly by day 13, consistent with the expected efficacy of adenoviral transduction (Figure 3A)
. The empty vector showed little effect on PAI-1 protein expression after correction with Lamin A/C for protein loading. Under these culture conditions, PAI-1 overexpression did not increase cell proliferation, as indicated by constant Lamin A/C expression. Importantly, the increase of PAI-1 protein expression in Wt PAI-1 but not empty vector-infected fibroblasts was accompanied by a corresponding increase in PAI-1-specific protease inhibitory activity (see below).
|
The effect of increased levels of PAI-1 was also studied in normal fibroblasts incorporated in fibrin gels, a situation that mimics the wound environment and where multiple phenotypic differences between keloid and normal fibroblasts have been observed.24,45
Fibroblasts in fibrin gels were infected at 30, 100, and 300 moi with Ad-Wt PAI-1 or empty vector and subsequently cultured for 6 days in 3% FBS. These conditions avoid gel lysis by normal cells under lower serum conditions45,46
and minimize possible effects of growth factors in higher serum concentrations. Ad-Wt PAI-1, but not empty vector, led to increased levels of PAI-1 protein in a viral dose-dependent manner (Figure 4A)
. Similar to the results in monolayer culture, increased PAI-1 production in fibrin gels stimulated the accumulation of newly synthesized collagen 3.3-fold (Figure 4B
; 300 moi). Similar results were obtained with a different normal cell strain, N-A (data not shown). In this fibrin gel culture model, empty vector had no effect on collagen. Thus, in a model of provisional matrix, normal fibroblasts still exhibited PAI-1-dependent collagen regulation.
|
To remove any ambiguity regarding PAI-1-dependent regulation of collagen caused by the stimulatory effect of empty vector and to demonstrate this PAI-1-dependent function in keloid fibroblasts in the absence of adenoviral vectors, we used a siRNA approach. Normal fibroblasts were transduced with Ad-Wt PAI-1 vector to increase both PAI-1 and collagen as described in Figure 3
. In this situation, the effects of adenoviral infection (either Wt PAI-1 or empty vector) on the accumulation of newly synthesized collagen were expected to remain after exposure to siRNAs targeted to PAI-1. Thus, if the only effect on collagen accumulation was due infection, siRNAs would be without effect; similarly, any reduction of collagen accumulation caused by siRNA would only be due to PAI-1-dependent regulation. Three different siRNA sequences targeting the human PAI-1 gene were used to decrease the level of PAI-1, and a mammalian nontargeting sequence siCONTROL siRNA was used as a negative control. Fluorescent siGLO was cotransfected with each targeting siRNA to follow transfection efficiency (
90%). This stable, fluorescent, non-targeting control siRNA has been modified so that it does not engage the RNA-induced silencing complex (RISC) system or interfere with target gene silencing. Transfection of normal fibroblasts with siRNA was performed in 10% FBS immediately before infection with Ad-Wt PAI-1. Cells were then cultured in 3% FBS for 6 days before analysis.
PAI-1 protein expression was reduced by more than 90% with each PAI-1-targeting siRNA sequence (siRNA5, siRNA6, and siRNA7) when compared with the nontargeting sequence siCONTROL siRNA (nontargeting siRNA) (Figure 5A
, open bars). This caused greater than 60% reduction in accumulation of newly synthesized collagen (Figure 5A
, filled bars). Given that the level of accumulation in the presence of the nontargeting sequence siRNA represents the sum of adenoviral (alone) and PAI-1-dependent increases in accumulation, the observed reductions caused by targeting siRNAs are consistent with elimination of the PAI-1-dependent effects (compare with Figure 3B
).
|
Next, we studied the effect of PAI-1 siRNA on PAI-1 expression and collagen accumulation by keloid fibroblasts. In this case, no adenoviral exposure was involved, but an unknown level of non-PAI-1-mediated support for keloid-specific collagen accumulation was expected. In addition to the individual PAI-1 siRNAs, we also used a mixture of the three siRNAs, because the effectiveness of the individual PAI-1 siRNAs varied in keloid fibroblasts. The mixture of PAI-1 siRNAs had the strongest effect (> 90%) on decreasing the level of PAI-1 protein in keloid fibroblasts (strain K-C3) compared with individual siRNAs (Figure 6A
, open bars). Treatment with siRNAs for PAI-1 also resulted in decreased accumulation of newly synthesized collagen; the siRNA mix provided the largest decrease, to
50%, when compared with the nontargeting sequence (Figure 6A
, filled bars). Using the siRNA mix and a different keloid cell strain, K-Ea, collagen accumulation was reduced to 30% of the nontargeting control (Figure 6B)
. Collectively, these siRNA experiments demonstrate that PAI-1 protein is capable of enhancing the accumulation of newly synthesized collagen and makes a significant contribution to the pathological levels of collagen accumulation produced by keloid fibroblasts.
|
To determine whether the effect of PAI-1 on the accumulation of newly synthesized collagen was mediated by its inhibition of protease activity or by its interference with Vn-dependent cell function, adenoviral vectors carrying PAI-1 mutant genes were used to infect normal fibroblasts and compared with Wt PAI-1 for their effect on collagen accumulation. Two mutants were studied, PAI-1INH– and PAI-1VN–; the former has been demonstrated to lack the capacity for protease inhibition, whereas the latter lacks the capacity to bind to Vn and alter its normal ligand interactions.42
Normal fibroblasts transduced with each of the three PAI-1 adenoviral vectors expressed a similar dose-dependent increase in PAI-1 protein expression (Figure 7A)
. However, at each dose, cells treated with PAI-1VN– expressed higher levels of mutant PAI-1 than occurred with Wt PAI-1 or the PAI-1INH– mutant. Importantly, the level of PAI-1-dependent protease inhibitory activity in PAI-1INH– mutant treated cells was <6% of that detected in Wt or VN– mutant treated cells (Figure 8A)
, in agreement with the original literature.42
Consequently, if protease inhibition is responsible for the effects of PAI-1 on collagen, this loss-of-function mutant should be >94% less effective than Wt PAI-1 (Figure 8A)
. The PAI-1VN– mutant caused a small fraction of the treated fibroblasts to round-up, consistent with its lack of association with the Vn.42
Fibroblasts from all other treatment groups exhibited morphology similar to uninfected cells (Figure 8B)
.
|
|
| Discussion |
|---|
|
|
|---|
Using seven strains of normal and keloid fibroblasts and different lengths and conditions of culture, we have exposed two clear differences that serve to characterize keloid fibroblasts; these are most easily recognized in Figure 2C
. First, under basal conditions (0.1% ITS+), keloid fibroblasts, but not normal fibroblasts, demonstrated a high but variable level of accumulation of newly synthesized collagen, inherent accumulation, associated with very low PAI-1 (values along the x axis). Second, only keloid fibroblasts responded to 3% FBS with large changes in collagen accumulation and PAI-1 expression, providing angular plots in Figure 2C
. Inherent collagen accumulation did not require exogenous serum-derived growth factors and was maintained at least 6 days. Such stability suggests the operation of autocrine or paracrine growth factor signaling. Similarly, elevated type I collagen gene expression after 24 hours of serum-free culture has recently been reported for keloid fibroblasts derived from three spontaneous keloids using genome-wide arrays.23
COL1A1 expression in fibroblasts from three different lesional locations, the expanding periphery, center bottom (origin), and center top (collapsing), was
8-fold higher than in normal controls. Although 24 hours of serum-free culture may not be adequate for complete decay of the effects of serum exposure, these results support the concept of cell-centric inherent collagen accumulation based on regulation of transcription/translation rather than collagen turnover, although both likely participate.
Considerable variation of inherent collagen accumulation is apparent in different strains of keloid fibroblasts in Figure 2C
. This may be due to genetic differences that mark susceptible individuals (rev. in Ref. 22
) or to differences in donor or lesion location. Because multiple aspects of the keloid phenotype may be differentially and independently retained/lost during subculture, we have sought to minimize this by using strains at less than three passages and by using direct enzymatic release from lesional tissue rather than a cell outgrowth technique. Similar culture protocols were used in the spontaneous keloid gene array study above23
and may increase the detection of keloid markers, including collagen expression. The importance of rapid isolation and characterization has also been demonstrated by the loss of integrin subpopulations in freshly isolated keloid fibroblasts within 4 days of culture.47
Such choices for analysis will also minimize cell selection but may allow inclusion of a small proportion vascular cells or epithelial cells that inform epithelial-mesenchymal communication to support the fibroblast keloid phenotype.18
The molecular mechanisms that drive inherent collagen accumulation and dictate other aspects of the keloid phenotype remain elusive, but several possibilities have been suggested by both gene arrays and directed studies. Among these are two that interact with the PAI-1-uPA system. Insulin-like growth factor binding proteins (IGFBPs) have been consistently identified in gene array studies as being markedly up-regulated in keloid fibroblasts.22,23,48 It is not clear whether the role of IGFBPs in fibrosis depends on insulin-like growth factor binding and the modulation of this by binding to collagen or Vn or on insulin-like growth factor-independent activity. However, the single manipulation of IGFBP5 overexpression in cultured normal lung fibroblasts by adenoviral transduction leads to marked increases in collagen and Fn production.49 Application of adenoviral expression of IGFBP5 to the in vivo environment has led to compelling models of skin50 and lung50 fibrosis.
Expression, processing, and signaling of the pro-fibrotic growth factor, TGF-β, provides multiple opportunities for initiation of pathology in a serum-free fibroblast-dependent autocrine environment. It influences PAI-1 by stimulating PAI-1 expression51 and by driving matrix synthesis that may be under PAI-1 regulatory control. In addition, TGF-β induction of PAI-1 prevents plasmin-dependent fibroblast apoptosis through its inhibition of plasminogen activation, providing a survival advantage for fibroblasts in an active fibrotic environment.40 TGF-β is up-regulated in keloid gene arrays,23 and protein expression of the β1- and β2-isoforms that increase incisional scaring52 has been reported in keloid fibroblasts.53 These cells also exhibit differential expression of TGF-β receptors I and II, increased Smad phosphorylation compared with normal fibroblasts,54 and suppression of TGF-β-induced collagen synthesis on exposure to a truncated type II TGF-β receptor.55 Pharmacological treatment with quercetin suppresses collagen and Fn expression in keloid fibroblasts due to TGF-β receptor and Smad down-regulation and decreased Smad2 and 3 activation.56 That a single alteration in TGF-signaling can lead to pathological fibrosis has been shown by the targeted expression of a kinase-negative TGF-β type II receptor mutant in transgenic mice. Low-level expression of this usually dominant-negative receptor distorts signaling from the type I receptor and leads to increased production and processing of TGF-β, increased expression of the wild-type type II receptor, and development of both skin and lung fibrosis mediated by the type I receptor.57,58 Regulation of collagen synthesis can also occur through the noncanonical TGF-β-activated kinase 1 (TAK1) pathway as we have shown by mimicking TGF-β-stimulated type II collagen synthesis using adenoviral overexpression of TGF-β-activated kinase 1 with or without its activator, TGF-β-activated kinase 1 binding protein 1.43
Regardless of whether the TGF-β and IGFBP pathways are responsible for inherent collagen accumulation under serum-free conditions, they both will be engaged during the transition from 0.1% ITS+ to 3% FBS because of the increase in exogenous TGF-β and insulin-like growth factor. Six of seven keloid strains exhibited simultaneous increases in PAI-1 expression and collagen accumulation as demonstrated in Figure 2C
. In contrast, during the transition from 3 to 10% FBS, six of seven keloid strains showed vertical plots, indicating that saturation of collagen accumulation but not PAI-1 occurred at
3% FBS. The uniformity of these transitions in keloid fibroblasts was unexpected. The only exception to saturation in 3% FBS was strain K-F (Supplemental Figure S3, angled plot), which exhibited continued increases in collagen and PAI-1 from 0.1% ITS+ to 10% FBS and produced the highest level of collagen accumulation. It is unclear why this strain diverges from the above pattern. However, strain K-F is unique in another way; it is the only strain that has a matched normal strain, N-(K-F), obtained from apparently normal perilesional tissue. The level of collagen accumulation and serum-response profile of N-(K-F) were midway between clustered normal and keloid strains (Figure 2C
; Supplemental Figure S3). This is consistent with an early stage of development of the keloid phenotype or a low percentage of mature keloid cells. For comparison, perilesional elevation of IGFBP expression has also been reported in patients with systemic sclerosis,49,59
and both observations suggest staging of pathological changes.
Serum induced, simultaneous increases in collagen accumulation and PAI-1 expression were expected because serum, and more specifically TGF-β, cause transactivation of both promoters.51
However, our previous work demonstrating inhibition of keloid collagen synthesis by PAI-1 neutralizing antibodies suggested a more direct link. We therefore asked whether direct specific manipulation of PAI-1 expression would alter collagen accumulation. Adenoviral expression of PAI-1 in normal fibroblasts provided a range of PAI-1 concentrations that mimicked or exceeded that produced by keloid fibroblasts and increased the accumulation of newly synthesized collagen. This effect of PAI-1 on collagen accumulation required considerable time to develop, because PAI-1 expression on day 2 with 300 moi was similar to that on day 6 with 100 moi (Figure 3A)
, and yet collagen accumulation was
3.5-fold higher on day 6 (Figure 3B
, compare black bars for these conditions). This is consistent with a cascade of events downstream of PAI-1 expression rather than an immediate result of its increased abundance. PAI-1 expression over 6 days caused a similar effect on normal cells cast in fibrin gels (Figure 4)
suggesting that this mechanism of enhancing collagen accumulation should be operational in the three-dimensional fibrin-dominated matrix of early wound repair.
Three different siRNA sequences were selected from the wild-type human PAI-1 coding sequence for our loss-of-function experiments. Each produced PAI-1 knockdown at the protein level and reduced collagen accumulation in the 6-day experimental protocol when PAI-1 and collagen accumulation were initially elevated by adenoviral overexpression of PAI-1 in normal cells. This result was replicated when a fourth PAI-1 sequence was targeted by expression of an shRNAmir using a lentiviral vector, demonstrating that the result was independent of the delivery mechanism and further demonstrating specificity to PAI-1. These complex RNA interference protocols take time to develop both the up-regulation of PAI-1 and the down-regulation of PAI-1 and collagen, and they may not be optimal. They clearly demonstrate, however, that both the increase and decrease of collagen accumulation are PAI-1 dependent and not the result of adenoviral infection (empty vector). As a test of the potential clinical relevance of PAI-1 siRNA in reducing collagen accumulation, this strategy was applied to two different keloid fibroblast strains, K-C3 and K-Ea. The most effective knockdown of both PAI-1 and collagen accumulation was provided by the mixture of all three siRNAs. This produced statistically significant 50 and 70% reductions, respectively, in collagen accumulation and brought accumulation near (K-C3) or within (K-Ea) the range of normal fibroblasts under the identical conditions used for these siRNA experiments (namely, 3% FBS and 6 days of culture) (Supplemental Figure S1A).
Collectively, these results demonstrate that PAI-1 drives at least a major part of collagen accumulation in keloid fibroblasts. PAI-1 is necessary but may not be sufficient for this function and may require cooperation with TGF-β and insulin-like growth factor-1, factors that enhance matrix synthesis. Much of the research on keloids and other fibrotic diseases has been focused on synthetic mechanisms rather than on those that alter matrix degradation/turnover. The principal role of PAI-1 is to balance the uPA/tissue type plasminogen activator-dependent generation of plasmin from plasminogen.25 Excess PAI-1 inhibits plasminogen activators and prevents plasmin generation and its activation of matrix metalloproteinases, including collagenases, as well as its proteolysis of matrix proteins, including fibrin44 and Fn.40 Thus, in the presence of PAI-1, even normal matrix synthesis would yield higher levels of matrix because of the lack of plasmin activity and its attendant matrix turnover. This is the predominant in vivo fibrotic mechanism in a model of kidney fibrosis in which a protease inhibitor-deficient mutant of PAI-1 that maintained its wild-type Vn binding capacity competitively displaced wild-type PAI-1 on tissue Vn. This led to increased plasmin activity and decreased collagen accumulation in a plasmin-dependent manner.60,61 Such a protease-dependent mechanism is consistent with direct effects of PAI-1 on collagen accumulation in keloid and normal fibroblasts but may be modulated by the excess of keloid IGFBP-5, which binds PAI-1 and reduces its inhibitory capacity.62
PAI-1 also exhibits effects on cells not related to its protease inhibitory capacity, some of which are mediated by binding to Vn (rev. in Ref. 25
). We have tested a protease inhibitory mutant and a Vn-binding mutant for their capacity to induce collagen accumulation. The latter was found to be equipotent with wild-type PAI-1. Thus Vn binding is dispensable for the effects of PAI-1 on collagen accumulation. The complete protease inhibitor mutant still retained
50% of the capacity of wild-type PAI-1 for inducing collagen accumulation. Because this is a cleavage-resistant mutant, it is expected to maintain its interactions with uPA without inhibiting the catalytic activity of uPA (R. Gerard, personal communication). The partial reduction in accumulation by the mutant may reflect the fact that PAI-1 uses protease inhibition and another of its functions to control accumulation or that protease inhibition is not significantly involved but a conformational change in the inhibitor mutant makes it less capable of enhancing collagen accumulation. It is important that the mutant is not limited in its activity by issues of access, because the mutant was simultaneously synthesized and secreted by infected cells and would efficiently compete with wild-type PAI-1 in all time- and location-dependent protein-protein interactions.
PAI-1 is capable of interacting with a range of binding partners that can directly or indirectly influence the biosynthetic and regulatory machinery of the cell. Such mechanisms may represent alternatives to protease inhibition/suppression of plasmin generation for PAI-1-mediated stimulation of the keloid phenotype. For example, PAI-1 binds to preformed uPA:uPAR complexes and then to very low density lipoprotein receptor to stabilize the phosphorylation of extracellular signal-regulated kinase 1/2 induced by uPA:uPAR. This extended activation of extracellular signal-regulated kinase renders the uPA signal mitogenic63
and may also enhance the effects of other growth factors that signal through or collaborate with extracellular signal-regulated kinase. Potentially more important is the role of PAI-1 in mediating integrin ligation. uPAR interacts with β1, β2, β3 and β5 integrins64
and one of these,
1β1-integrin, is a principle collagen I receptor in mesenchymal cells and is elevated in keloid fibroblasts.47
This integrin has been proposed as a key mediator of matrix collagen feedback on collagen synthesis, based on the dermal phenotype of
1-integrin-null mice65
The observations are important because PAI-1 has been shown to cause disengagement of
vβ3 from its matrix ligands, including collagen and Fn in a variety of cell types by binding to uPA:uPAR complexes and subsequently causing endocytosis and recycling of the integrin.37
This process is mediated by PAI-1 binding to uPA:uPAR-integrin complexes, reducing integrin affinity for its ligand. Disengagement of the integrin would suppress its outside-in signaling as described for integrin-specific antibodies66
and reduce its feedback inhibition of collagen synthesis, leading to collagen accumulation. We have shown that keloid fibroblasts are responsive to matrix feedback by demonstrating that their collagen synthesis was dramatically reduced when cultured in three-dimensional collagen gels,24
and similar cultures have shown that such inhibition is less profound in
1-integrin-null fibroblasts than in normal cells.65
Thus, a speculative PAI-uPA-uPAR-
1 or β5-integrin-mediated feedback regulatory pathway may provide a substantial part of the increased collagen accumulation characteristic of the keloid phenotype. Such a mechanism may cooperate with the recently described function of uPAR-associated protein/Endo180 in fibroblast-mediated collagen degradation,67
where a role for PAI-1 has not yet been described. Validation of these mechanisms will require focused experiments to demonstrate the function of each element and the whole as well as its operation in keloid fibroblasts.
The decrease in collagen accumulation by keloid fibroblasts treated either with PAI-1 siRNAs, as shown in this study, or by PAI-1 neutralizing antibody, as in our previous study,24 establishes a novel PAI-1-mediated regulatory intervention for keloids that may be useful in the clinical setting. RNA interference has been shown to be effective at decreasing PAI-1 expression and consequently increasing adherence in vascular endothelial cells68 and suppressing replicative senescence.69 It is not known, however, whether siRNA targeted to PAI-1 can be effective in dermal fibroblasts maintained for long periods of time in three-dimensional models of fibroplasia45 and in diverse samples of keloid fibroblasts, using collagen synthesis as the outcome measure. Only when this has been demonstrated can investigations proceed to in vivo delivery techniques for eventual prophylactic treatment of patients at risk for keloid formation.
|
|
|
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by National Institute of Health grant R01GM055081 (to T.-L.T.) and by the Los Angeles Orthopaedic Hospital Foundation (to P.D.B.).
T.-L.T. and P.B. contributed equally to this work.
Supplemental material for this article can be found on http://ajp.amjpathol.org.
Accepted for publication July 31, 2008.
| References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |